March 8, 2024
Company

SIIX Corporation

Representative

Koji Yanase, President(Ticker code: 7613, Prime Market of Tokyo Stock Exchange)
Inquiries

Masaki Murakami, Executive officer & General Manager,
Investor & Public Relations Department(TEL: +81-6-6266-6400）

Announcement of Acquisition of a new share of Renzoku Biologics Inc.,
which engaged in the CDMO business (contract manufacturing and development of bio-antibody medicines),
through a third-party allotment and making them SIIX’s subsidiary.
SIIX Corporation (hereinafter “SIIX”) hereby announces the decision, taken at a meeting of the board of directors held today as
described below, to invest in Renzoku Biologics Inc. (hereinafter “Renzoku”), a biopharmaceutical CDMO business (contract
manufacturing and development business), and acquire shares of Renzoku.

1. Background
Recent progress in basic research in the life science field has led to an increase in the proportion of biopharmaceuticals in thepharmaceutical market, making biopharmaceuticals a growth area in the pharmaceutical sector. On the other hand, pharmaceuticalcompanies are taking longer to develop medicines, and the success rate of medicine development is declining. Biopharmaceuticals,
especially those using microorganisms and cells, have complex manufacturing processes, and the cost of developing and producing
them is significantly higher than for small molecule medicines.
The current standard production method for biopharmaceuticals, especially antibody medicines, is the batch production method
equipped with large culture vessels, but this method is not suitable for small-lot, multi-product production due to the large
investment in facilities and the difficulty of flexible production scale adjustment.
The world's leading pharmaceutical companies are maximizing the use of internal and external contract manufacturing
capabilities to ensure the successful development of new medicines. On the other hand, it is difficult for startup companies andresearch institutions with limited financial resources to utilize large-scale biopharmaceutical manufacturing facilities with highcosts, and there are many structurally unmet latent demands in the market as the trend of horizontal division of labor continues inthe biopharmaceutical industry.
Renzoku's mission is to contribute to the strengthening of the Japanese drug discovery ecosystem through innovation in the fieldof biopharmaceutical production, and to contribute to the health and medical care of patients worldwide who are waiting forbiopharmaceuticals. To realize this goal, we aim to bring innovation and meet unmet needs in the field of biopharmaceuticalproduction by accelerating the industrial application of advanced production technologies, including end-to-end, fully continuous
production technology that integrates the cell culture process with the separation and purification process of target proteins.
Through our investment in Renzoku, we will support to utilize the technology for fully continuous production of antibody
medicines to solve society's problems and will use this technology as the basis for a new biopharmaceutical CDMO business.
Fully continuous production technology is a next-generation production method that can achieve high production efficiency andcost-effectiveness, as well as flexibility in responding to small-quantity, high-mix production, because it has the advantage ofsmaller volume fermenters and a compact footprint.
We will combine DX/ICT-based operation management and automation/manpower-saving technologies such as data visualization,
quantification, visualization, and remote operation, for which we have a deep knowledge as a leading company in the EMS industry,and optimize their use for the continuous production of biopharmaceuticals. We will also apply our global experience in horizontal
specialization, which is leading the electronics industry, for the efficient design and operation of next-generation biopharmaceuticalplants.
1/2

SIIX Corporation
Prime market of Tokyo Stock Exchange 〈7613〉

2. Method of investment
SIIX will acquire new shares of Renzoku to be issued through a third-party allotment as of March 11.
Number of Renzoku’s shares issued :(before share issuance)
7,500,000 shares(after share issuance)
185,625,000 shares*After the new share issuance, SIIX will acquire 178,125,000 of Renzoku’s shares (stockholding ratio: 96%) (2,375 million JPY) through a third-party allotment.
(reference) Renzoku’s capital after share issuance:
1,195 million JPY
3. Outline of Renzoku
Company nameRenzoku Biologics Inc.

Location

20F, Marunouchi Trust Tower, 1-8-3, Marunouchi Chiyoda-ku, Tokyo, Japan

Representative

Dr. Hitoshi Kuboniwa, Chief Executive Officer

Establishment

August 22, 2023

Capital

7.5 million JPY

Major shareholder andShareholding

Dr. Hitoshi Kuboniwa 30.0%,
Other 4 Individual shareholders (as of before the share issuance)

Fiscal year-End

December 31

Business Description

Contract development and manufacturing of bio-antibody medicine, etc.

Relationship with SIIX

CapitalThere is no capital relationship between SIIX and Renzoku. In addition, there isno capital relationship between the related parties and affiliated companies of
SIIX and those of Renzoku or its affiliated companies.

Personnel

SIIX's director, executive officer and associate executive officer will serve asdirector and auditor of Renzoku.

Business

There is no business relationship between SIIX and Renzoku. In addition, there
is no business relationship between the related parties and affiliated companiesof SIIX and those of Renzoku or its affiliated companies.

4. Schedules
March 8, 2024
March 11, 2024

Decisions at the meeting of the board of directors (today)
Payment of capital contribution (plan)

5. Impact on our financial forecast
Upon completion of the investment, Renzoku is expected to become a consolidated subsidiary of SIIX, and wewill promptly announce its consolidated earnings forecast for the fiscal year ending December 31, 2024, should it
become necessary to revise its earnings forecast.

2/2

SIIX Corporation
Prime market of Tokyo Stock Exchange 〈7613〉